Head-to-head · Cost-Efficiency Index
Medivive vs OlleveCare
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Medivive
Cost-first shoppers who want not applicable to GLP-1 weight loss -- this is an NAD+ longevity product, non-fit for this category.
Visit MediviveOlleveCare
Shoppers already confirmed in one of its 13 covered jurisdictions who don't mind booking before seeing a price.
Visit OlleveCareThe verdict
Medivive and OlleveCare tie on the Cost-Efficiency Index at 43/100, so neither wins outright on the numbers. For most shoppers we'd start with Medivive (ranked #498, a hair above #499) — Cost-first shoppers who want not applicable to GLP-1 weight loss -- this is an NAD+ longevity product, non-fit for this category. But OlleveCare is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Medivive.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Medivive | OlleveCare |
|---|---|---|
| Cost-Efficiency Index | 43/100 | 43/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | 13 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #498 | #499 |
Medivive
43/100Where the value is
- Uses a LegitScript-certified, PCAB-accredited 503A pharmacy (Chemistry Rx) for compounding
- Manufacturing tied to an FDA-registered 503B facility (VeV Scientific)
- Clear single-product focus suggests less scope creep than multi-service platforms
The tradeoffs
- Does not prescribe or sell semaglutide, tirzepatide, or any GLP-1 medication
- No pricing disclosed anywhere on the site for its actual NAD+ product
OlleveCare
43/100Where the value is
- Publishes a specific, checkable list of covered jurisdictions rather than a vague 'most states' claim
- Issues superbills so cash-pay patients can attempt insurance reimbursement, unlike many pure-compounding competitors
- States plainly that lab work 'may be required,' setting an expectation of clinical monitoring rather than a pure prescription mill
The tradeoffs
- No GLP-1 price is published anywhere on the public site — the fee only appears inside the booking calendar after starting the process
- Coverage is limited to 13 jurisdictions, notably narrower than most 50-state compounded-GLP-1 competitors
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.